
Illumina (ILMN) Stock Forecast & Price Target
Illumina (ILMN) Analyst Ratings
Bulls say
Illumina is currently well-positioned in the centralized model of the sequencing industry, and management continues to plan for innovation in the holistic workflow rather than just speed or price. They also maintain transparency with customers on the long-term roadmap, instilling confidence in their future prospects. With strategic pricing decisions and strong gross margins in their consumables segment, Illumina has a solid foundation for continued growth in the clinical market. Despite temporary challenges in the academic market, we expect Illumina's new product offerings and increasing demand for clinical applications to support eventual stability in academic demand. However, there are risks associated with Illumina's academic and China market, as well as potential competition in the future.
Bears say
Illumina is facing concerns about their quarterly expectations and instrument placements, as well as discounting on high-throughput instruments. However, their focus on capturing longer-term business and strong demand for their instruments from clinical customers indicate a hold on the clinical sequencing market. Overall, with their strong position in the clinical market and potential for sustained revenue growth, Illumina maintains a favorable risk/reward for investors.
This aggregate rating is based on analysts' research of Illumina and is not a guaranteed prediction by Public.com or investment advice.
Illumina (ILMN) Analyst Forecast & Price Prediction
Start investing in Illumina (ILMN)
Order type
Buy in
Order amount
Est. shares
0 shares